USTR holds hearing on Germany pharmaceutical Section 301 investigation

What happened

U.S. Trade Representative held a public hearing on 22 Sep 2026 as part of its Section 301 investigation into Germany's policies concerning payments for innovative pharmaceutical products.

Why it matters

The investigation could eventually lead to trade measures if the authority determines that the practices are actionable. No new tariff or duty change was announced in this notice.

Who should watch

• Pharmaceutical manufacturers
• Pharmaceutical exporters
• Companies exposed to United States–Germany pharmaceutical trade
• Relevant regulatory and compliance teams

What to watch next

• Monitor the hearing record.
• Watch for a future determination.
• Watch for any proposed trade action.
• Confirm pharmaceuticals product and industry scope.

Official source

U.S. Trade Representative · 21 Sep 2026 · Official source

Related developments

• Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals · 23 Sep 2026
• Notice of Reduction of Tariffs on Patented Pharmaceuticals and Pharmaceutical Ingredients · 4 Aug 2026
• Germany updates import compliance and customs declaration requirements · 7 Jul 2026
• Germany trade compliance screening intensifies for sensitive and dual-use shipments · 4 Jul 2026